We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Rejects Allergan’s Levadex Due to CMO Concerns
FDA Rejects Allergan’s Levadex Due to CMO Concerns
May 6, 2013
Allergan has received a complete response letter (CRL) for its aerosol-based migraine drug Levadex.